The combination of trastuzumab and cytotoxic chemotherapy, mainly taxanes, has been shown to significantly improve outcomes for women with HER2-overexpressing breast cancer, improving time to disease progression and overall survival [6]. This evidence concerns the gene ERBB2 and breast cancer.